arginine has been researched along with sorafenib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T | 1 |
| Hoshida, Y; Kishikawa, T; Koike, K; Kojima, K; Kondo, Y; Noyama, T; Ohishi, M; Ohno, M; Ota, S; Otsuka, M; Sato, M; Shibata, C; Soga, T; Sun, X; Takata, A; Takehana, K; Tan, PS; Yoshikawa, T | 1 |
1 review(s) available for arginine and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for arginine and sorafenib
| Article | Year |
|---|---|
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2013 |
Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.
Topics: Animals; Apoptosis; Arginine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |